VCYT · Veracyte, Inc.
$41.25
-1.35 (-3.17%)
At close · Aug 14
Market Cap
$3.32B
Shares
80.39M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$41.25
Open$42.54
Day$41.00–43.13
52W close$28.61–60.49
Avg vol 30d1.2M
Short int6.9M · 8.5% float · 4.8d
Short vol57%
Last earningsJul 30, 2026
DataJan 2020–Aug 2026
Filing10-Q · Jul 31
Up next
Next earnings call
Oct 26, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Jul 31, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−3%
below
Price vs 50-day avg
−22%
below
RSI (14)
29
oversold
MACD trend
Negative
52-week position
40%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−30%
trailing
6-month return
+15%
trailing
YTD return
−2%
this year
Relative strength
+2%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $53 › 200d $42 — 50d above 200d
Institutional flow
Accumulating
+8% holders QoQ · +75 funds added
Insider flow
Distributing
Net -$1.1M over 90 days · 100% sells
Short interest
Rising
8.53% of float · ▲ +2.8% MoM · 4.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
363 holders — near 3-yr high, broad support
Squeeze score
58
elevated · 0–100
Fundamentals
Revenue growth
+16%
Y/Y
Gross margin
70%
expanding
EPS growth
+165%
Y/Y
Free cash flow
$126.6M
Valuation
P/E 29.5
below peers
Balance sheet
$362.6M
net cash
Quant / Vol
risk profile
Volatility
63%
annualized · 1-yr
Max drawdown
−39%
past year
ATR
7.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jul 30, 2026
Total revenue
· 2026
$590M – $596M
Testing revenue
· 2026
$576M – $582M
Prior guidance
period ended
· from the 8-K filed Nov 4, 2025
Testing revenue
· full year 2025
$484M – $487M
Total revenue
· full year 2025
$506M – $510M
Adjusted EBITDA as a percentage of revenue
· full year 2025
at least 25%
Guided vs delivered
· last 2 settled
Total revenue
full year 2025
guided $506M – $510M
$517.15M
Beat +1.8%
Total revenue
2024
guided $394M – $402M
$445.76M
Beat +12.0%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−3%
Neutral
Price vs 50-day avg
−22%
Bearish
RSI (14)
29
Neutral
MACD trend
Negative
Bearish
52-week position
40%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $53 › 200d $42 — 50d above 200d
Institutional flow
Accumulating
+8% holders QoQ · +75 funds added
Insider flow
Distributing
Net -$1.1M over 90 days · 100% sells
Short interest
Rising
8.53% of float · ▲ +2.8% MoM · 4.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
363 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $29
Now $41 · 40%
Range high $60
vs 200-day avg -3%
vs 50-day avg -22%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA as a % of Revenue non-GAAP | 29.2% | second quarter of 2026 | — |
|
|
|||
| Afirma volume | 18,600 | second quarter of 2026 | — |
|
|
|||
| Decipher volume | 29,700 | second quarter of 2026 | — |
|
|
|||
| Testing volume | 48,389 | second quarter of 2026 | — |
|
|
|||
| Total volume | 50,967 | second quarter of 2026 | — |
|
|
|||
| Adjusted EBITDA non-GAAP | $42.8M | Q1 2026 | — |
|
|
|||
| Cash from operations | $35.2M | Q1 2026 | — |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VCYT
this stock
Veracyte, Inc.
|
$3.32B | -2.0% | +16.0% | 29.5 | 8.5% |
|
TMO
Thermo Fisher Scientific Inc.
|
$217.52B | +1.5% | +14.5% | 31.7 | 1.3% |
|
DHR
Danaher Corp /De/
|
$142.32B | -11.6% | +8.5% | 35.9 | 1.7% |
|
NTRA
Natera, Inc.
|
$44.67B | +35.3% | -2.8% | — | 3.0% |
|
IDXX
Idexx Laboratories Inc /De
|
$43.41B | -18.6% | +10.4% | 38.7 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VCYT | -12.6% | -30.2% | +15.4% | -11.0% | -2.0% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -13.0% | -34.7% | +1.6% | -14.9% | -15.9% |
Key facts
CIK
1384101
CUSIP
92337F107
13F (30d)
343 filings
342 filers
Visit website
Investor relations